Literature DB >> 14717922

The classification of glomerulonephritis in systemic lupus erythematosus revisited.

Jan J Weening1, Vivette D D'Agati, Melvin M Schwartz, Surya V Seshan, Charles E Alpers, Gerald B Appel, James E Balow, Jan A Bruijn, Terence Cook, Franco Ferrario, Agnes B Fogo, Ellen M Ginzler, Lee Hebert, Gary Hill, Prue Hill, J Charles Jennette, Norella C Kong, Philippe Lesavre, Michael Lockshin, Lai-Meng Looi, Hirofumi Makino, Luiz A Moura, Michio Nagata.   

Abstract

The currently used classification reflects our understanding of the pathogenesis of the various forms of lupus nephritis, but clinicopathologic studies have revealed the need for improved categorization and terminology. Based on the 1982 classification published under the auspices of the World Health Organization (WHO) and subsequent clinicopathologic data, we propose that class I and II be used for purely mesangial involvement (I, mesangial immune deposits without mesangial hypercellularity; II, mesangial immune deposits with mesangial hypercellularity); class III for focal glomerulonephritis (involving <50% of total number of glomeruli) with subdivisions for active and sclerotic lesions; class IV for diffuse glomerulonephritis (involving > or =50% of total number of glomeruli) either with segmental (class IV-S) or global (class IV-G) involvement, and also with subdivisions for active and sclerotic lesions; class V for membranous lupus nephritis; and class VI for advanced sclerosing lesions. Combinations of membranous and proliferative glomerulonephritis (i.e., class III and V or class IV and V) should be reported individually in the diagnostic line. The diagnosis should also include entries for any concomitant vascular or tubulointerstitial lesions. One of the main advantages of the current revised classification is that it provides a clear and unequivocal description of the various lesions and classes of lupus nephritis, allowing a better standardization and lending a basis for further clinicopathologic studies. We hope that this revision, which evolved under the auspices of the International Society of Nephrology and the Renal Pathology Society, will contribute to further advancement of the WHO classification.

Entities:  

Mesh:

Year:  2004        PMID: 14717922     DOI: 10.1111/j.1523-1755.2004.00443.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  354 in total

1.  Auto-antibody production and glomerulonephritis in congenic Slamf1-/- and Slamf2-/- [B6.129] but not in Slamf1-/- and Slamf2-/- [BALB/c.129] mice.

Authors:  Marton Keszei; Yvette E Latchman; Vijay K Vanguri; Daniel R Brown; Cynthia Detre; Massimo Morra; Carolina V Arancibia-Carcamo; Carolina V Arancibia; Elahna Paul; Silvia Calpe; Wilson Castro; Ninghai Wang; Cox Terhorst; Arlene H Sharpe
Journal:  Int Immunol       Date:  2011-01-28       Impact factor: 4.823

2.  Anti-C1q antibody is a valuable biological marker for prediction of renal pathological characteristics in lupus nephritis.

Authors:  Zhu Chen; Guo-Sheng Wang; Gui-Hong Wang; Xiang-Pei Li
Journal:  Clin Rheumatol       Date:  2012-06-14       Impact factor: 2.980

Review 3.  Histopathology of lupus nephritis.

Authors:  Konstantinos Giannakakis; Tullio Faraggiana
Journal:  Clin Rev Allergy Immunol       Date:  2011-06       Impact factor: 8.667

4.  Bacterial lipopeptide triggers massive albuminuria in murine lupus nephritis by activating Toll-like receptor 2 at the glomerular filtration barrier.

Authors:  Rahul D Pawar; Liliana Castrezana-Lopez; Ramanjaneyulu Allam; Onkar P Kulkarni; Stephan Segerer; Ewa Radomska; Tobias N Meyer; Catherine-Meyer Schwesinger; Nese Akis; Hermann-Josef Gröne; Hans-Joachim Anders
Journal:  Immunology       Date:  2008-10-24       Impact factor: 7.397

Review 5.  An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases.

Authors:  Alice S Appel; Gerald B Appel
Journal:  Nat Clin Pract Nephrol       Date:  2009-01-27

6.  The Synergy of Endotoxin and (1→3)-β-D-Glucan, from Gut Translocation, Worsens Sepsis Severity in a Lupus Model of Fc Gamma Receptor IIb-Deficient Mice.

Authors:  Jiraphorn Issara-Amphorn; Saowapha Surawut; Navaporn Worasilchai; Arthid Thim-Uam; Malcolm Finkelman; Ariya Chindamporn; Tanapat Palaga; Nattiya Hirankarn; Prapaporn Pisitkun; Asada Leelahavanichkul
Journal:  J Innate Immun       Date:  2018-01-31       Impact factor: 7.349

7.  Spectrum of systemic lupus erythematosus in Oman: from childhood to adulthood.

Authors:  Asma Al Rasbi; Eiman Abdalla; Rabab Sultan; Nasreen Abdullah; Juma Al Kaabi; Ibrahim Al-Zakwani; Reem Abdwani
Journal:  Rheumatol Int       Date:  2018-05-02       Impact factor: 2.631

8.  Activated CD4+ T cells target mesangial antigens and initiate glomerulonephritis.

Authors:  Yogesh Scindia; Dominika Nackiewicz; Paromita Dey; Agnieszka Szymula; Amandeep Bajwa; Diane L Rosin; W Kline Bolton; Mark D Okusa; Umesh Deshmukh; Harini Bagavant
Journal:  Nephron Exp Nephrol       Date:  2012-10-19

9.  Autoantibodies against C-Reactive Protein Influence Complement Activation and Clinical Course in Lupus Nephritis.

Authors:  Qiu-Yu Li; Hai-Yun Li; Ge Fu; Feng Yu; Yi Wu; Ming-Hui Zhao
Journal:  J Am Soc Nephrol       Date:  2017-05-31       Impact factor: 10.121

Review 10.  [Renal manifestations of rheumatic diseases].

Authors:  A Schwarting; E Märker-Hermann
Journal:  Z Rheumatol       Date:  2005-02       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.